Cargando…

Incidence of high chromogranin A serum levels in patients with non metastatic prostate adenocarcinoma

BACKGROUND: ChromograninA in prostate carcinoma (PC) indicate NE differentiation. This tumour is more aggressive and resistant to hormone therapy. PATIENTS AND METHODS: We analyzed the incidence of pre-operative ChromograninA serum levels in non metastatic PC patients. Serum PSA and ChromograninA we...

Descripción completa

Detalles Bibliográficos
Autores principales: Appetecchia, Marialuisa, Meçule, Aurela, Pasimeni, Giuseppe, Iannucci, Concetta V, De Carli, Piero, Baldelli, Roberto, Barnabei, Agnese, Cigliana, Giovanni, Sperduti, Isabella, Gallucci, Michele
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3018395/
https://www.ncbi.nlm.nih.gov/pubmed/21162758
http://dx.doi.org/10.1186/1756-9966-29-166
_version_ 1782196055763320832
author Appetecchia, Marialuisa
Meçule, Aurela
Pasimeni, Giuseppe
Iannucci, Concetta V
De Carli, Piero
Baldelli, Roberto
Barnabei, Agnese
Cigliana, Giovanni
Sperduti, Isabella
Gallucci, Michele
author_facet Appetecchia, Marialuisa
Meçule, Aurela
Pasimeni, Giuseppe
Iannucci, Concetta V
De Carli, Piero
Baldelli, Roberto
Barnabei, Agnese
Cigliana, Giovanni
Sperduti, Isabella
Gallucci, Michele
author_sort Appetecchia, Marialuisa
collection PubMed
description BACKGROUND: ChromograninA in prostate carcinoma (PC) indicate NE differentiation. This tumour is more aggressive and resistant to hormone therapy. PATIENTS AND METHODS: We analyzed the incidence of pre-operative ChromograninA serum levels in non metastatic PC patients. Serum PSA and ChromograninA were analyzed before treatment. Clinicopathological parameters were evaluated in relation to serum ChromograninA. 486 patients were enrolled. RESULTS: We found 352 pT2 and 134 pT3. 21 patients were N+. 278 patients had Gleason score levels <7; 173 patients had levels = 7 (122 were 3+4 and 51 4+3); and 35 patients with levels >7. Median PSA pre-operative level was 7.61 ng/ml. PSA was significantly associated with pT stage (pT2 with PSA abnormal 23.6% vs pT3 48.5%, p < 0.0001) and with a Gleason score (PSA abnormal 60% in the Gleason score was >7 vs 29.5% in the Gleason score = 7 vs 27.3% in the Gleason score <7, p < 0.0001). In 114 patients pre-operative ChromograninA levels were elevated (23.5%). Serum ChromograninA levels had no significant association with PSA (p = 0.44) and pT stage (p = 0.89). abnormal ChromograninA levels increased from a Gleason score of <7 (25.5%) to >7 (31.4%) (p = 0.12). The serum ChromograninA levels in the two groups of patients were subdivided before and after 2005 on the basis of different used assays, showing no correlation with serum ChromograninA and other parameters. CONCLUSIONS: This study showed that ChromograninA levels correlated to NE differentiation and possible aggressiveness of PC. Pre-operative circulating ChromograninA could complement PSA in selecting more aggressive PC cases, particularly in the presence of a higher Gleason score. Complementary information is provided by the absence of a correlation between serum ChromograninA and PSA levels.
format Text
id pubmed-3018395
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30183952011-01-11 Incidence of high chromogranin A serum levels in patients with non metastatic prostate adenocarcinoma Appetecchia, Marialuisa Meçule, Aurela Pasimeni, Giuseppe Iannucci, Concetta V De Carli, Piero Baldelli, Roberto Barnabei, Agnese Cigliana, Giovanni Sperduti, Isabella Gallucci, Michele J Exp Clin Cancer Res Research BACKGROUND: ChromograninA in prostate carcinoma (PC) indicate NE differentiation. This tumour is more aggressive and resistant to hormone therapy. PATIENTS AND METHODS: We analyzed the incidence of pre-operative ChromograninA serum levels in non metastatic PC patients. Serum PSA and ChromograninA were analyzed before treatment. Clinicopathological parameters were evaluated in relation to serum ChromograninA. 486 patients were enrolled. RESULTS: We found 352 pT2 and 134 pT3. 21 patients were N+. 278 patients had Gleason score levels <7; 173 patients had levels = 7 (122 were 3+4 and 51 4+3); and 35 patients with levels >7. Median PSA pre-operative level was 7.61 ng/ml. PSA was significantly associated with pT stage (pT2 with PSA abnormal 23.6% vs pT3 48.5%, p < 0.0001) and with a Gleason score (PSA abnormal 60% in the Gleason score was >7 vs 29.5% in the Gleason score = 7 vs 27.3% in the Gleason score <7, p < 0.0001). In 114 patients pre-operative ChromograninA levels were elevated (23.5%). Serum ChromograninA levels had no significant association with PSA (p = 0.44) and pT stage (p = 0.89). abnormal ChromograninA levels increased from a Gleason score of <7 (25.5%) to >7 (31.4%) (p = 0.12). The serum ChromograninA levels in the two groups of patients were subdivided before and after 2005 on the basis of different used assays, showing no correlation with serum ChromograninA and other parameters. CONCLUSIONS: This study showed that ChromograninA levels correlated to NE differentiation and possible aggressiveness of PC. Pre-operative circulating ChromograninA could complement PSA in selecting more aggressive PC cases, particularly in the presence of a higher Gleason score. Complementary information is provided by the absence of a correlation between serum ChromograninA and PSA levels. BioMed Central 2010-12-17 /pmc/articles/PMC3018395/ /pubmed/21162758 http://dx.doi.org/10.1186/1756-9966-29-166 Text en Copyright ©2010 Appetecchia et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<url>http://creativecommons.org/licenses/by/2.0</url>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Appetecchia, Marialuisa
Meçule, Aurela
Pasimeni, Giuseppe
Iannucci, Concetta V
De Carli, Piero
Baldelli, Roberto
Barnabei, Agnese
Cigliana, Giovanni
Sperduti, Isabella
Gallucci, Michele
Incidence of high chromogranin A serum levels in patients with non metastatic prostate adenocarcinoma
title Incidence of high chromogranin A serum levels in patients with non metastatic prostate adenocarcinoma
title_full Incidence of high chromogranin A serum levels in patients with non metastatic prostate adenocarcinoma
title_fullStr Incidence of high chromogranin A serum levels in patients with non metastatic prostate adenocarcinoma
title_full_unstemmed Incidence of high chromogranin A serum levels in patients with non metastatic prostate adenocarcinoma
title_short Incidence of high chromogranin A serum levels in patients with non metastatic prostate adenocarcinoma
title_sort incidence of high chromogranin a serum levels in patients with non metastatic prostate adenocarcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3018395/
https://www.ncbi.nlm.nih.gov/pubmed/21162758
http://dx.doi.org/10.1186/1756-9966-29-166
work_keys_str_mv AT appetecchiamarialuisa incidenceofhighchromograninaserumlevelsinpatientswithnonmetastaticprostateadenocarcinoma
AT meculeaurela incidenceofhighchromograninaserumlevelsinpatientswithnonmetastaticprostateadenocarcinoma
AT pasimenigiuseppe incidenceofhighchromograninaserumlevelsinpatientswithnonmetastaticprostateadenocarcinoma
AT iannucciconcettav incidenceofhighchromograninaserumlevelsinpatientswithnonmetastaticprostateadenocarcinoma
AT decarlipiero incidenceofhighchromograninaserumlevelsinpatientswithnonmetastaticprostateadenocarcinoma
AT baldelliroberto incidenceofhighchromograninaserumlevelsinpatientswithnonmetastaticprostateadenocarcinoma
AT barnabeiagnese incidenceofhighchromograninaserumlevelsinpatientswithnonmetastaticprostateadenocarcinoma
AT ciglianagiovanni incidenceofhighchromograninaserumlevelsinpatientswithnonmetastaticprostateadenocarcinoma
AT sperdutiisabella incidenceofhighchromograninaserumlevelsinpatientswithnonmetastaticprostateadenocarcinoma
AT galluccimichele incidenceofhighchromograninaserumlevelsinpatientswithnonmetastaticprostateadenocarcinoma